Genticel signs deal to evaluate Roche Molecular Systems' HPV test

7 January 2016

Genticel (Euronext Paris: FR00011790542) on Thursday said it has signed an agreement with Roche Molecular Systems, a unit of Swiss pharma giant Roche (ROG: SIX), to evaluate Roche's cobas HPV Test.

The deal is in preparation for the planned Phase III trial of GTL001, Genticel's most advanced therapeutic vaccine candidate against HPV 16/18 infections.

Benedikt Timmerman, chief executive of Genticel, said: "We are very pleased to enter into this agreement with Roche Molecular Systems," concluded. "The ability to evaluate the cobas HPV Test is an important milestone that will help us anticipate requirements for the planned Phase III program of GTL001 and identify the patient population that will most benefit from treatment."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK